Bolt Biotherapeutics, Inc. (BOLT)

Market Cap	8.77M
Revenue (ttm)	4.17M
Net Income (ttm)	-50.71M
Shares Out	1.92M
EPS (ttm)	-26.48
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	135,798
Open	4.610
Previous Close	4.700
Day's Range	4.450 - 4.850
52-Week Range	4.420 - 13.000
Beta	0.92
Analysts	Buy
Price Target	34.00 (+643.98%)
Earnings Date	Nov 12, 2025

About BOLT

Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company dBDC-3042, develops dan agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple-negative breast, and other cancer; and BDC-4182, an next-generation boltbody technology platform that targets claudin 18.2, which is overexpressed in gastric/gastroesophageal junction cancer, pancreatic cancer, and other tumor types. The company has ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Feb 5, 2021
• Employees: 52
• Stock Exchange: NASDAQ
• Ticker Symbol: BOLT
• Website: https://www.boltbio.com

Financial Performance

In 2024, Bolt Biotherapeutics's revenue was $7.69 million, a decrease of -2.36% compared to the previous year's $7.88 million. Losses were -$63.12 million, -8.79% less than in 2023.

Analyst Summary

According to 4 analysts, the average rating for BOLT stock is "Buy." The 12-month stock price target is $34.0, which is an increase of 643.98% from the latest price.

Price Target

$34.0

(643.98% upside)

Analyst Consensus: Buy